After Alzheimers disease, VaD is one of the most common dementias, afflicting between one and three percent of people. It is a type of dementia caused by blood vessel disease or small strokes in the brain. It results in problems with memory, thinking, and behaviour and interferes with a person's ability to work and to carry out everyday tasks such as bathing, cooking and dressing. There are already drugs such as cholinesterase inhibitors that are effective in the treatment of cognitive and memory function in dementia, but these drugs are expensive and have side effects. This study was carried out on 120 patients diagnosed with mild to moderate VaD lasting three months or more at the Beijing Dongzhimen Hospital over a twelve-week period. The patients were randomly divided into two groups who received either the gastrodine compound granule (70 patients) or the drug usually used for stroke patients in China, Duxila (almitrine and raubasine; 50 patients). Both groups received their medications dissolved in hot water and given orally three times a day for twelve weeks.
On the basis of a test that measures mental states (mini-mental state exam) the patients in the gastrodine and Duxila groups showed significant improvement at the end of the study over their baseline scores. There were similar improvements in both groups with respect to memory, orientation, calculations, and language. However, the gastrodine group exhibited significant differences on a test (the Blessed Behavioural Scale) designed to measure Behavioural characteristics, including daily living activities, personality, and behaviour, between their beginning and ending scores and between the gastrodine group and the Duxila group. Furthermore, the study found indications that gastrodine treatment may have increased regional cerebral blood flow in the VaD patients, but this finding requires confirmatory studies. The lead researcher in this study, Jinzhou Tian. M.D., Ph.D., Director of the Institute of Geriatrics, Beijing University of Chinese Medicine, said that broader and longer-term studies, at least six months or more, are necessary to determine the clinical benefits of the gastrodine compound for patients with mild to moderate cognitive impairment from ischemic VaD. Given the positive results so far, however, further studies into herbal therapies for VaD may well be warranted.
This is yet another case in which the wisdom of traditional Chinese culture rises once again to humanitys attention. In this case, it is a compound from traditional Chinese medicine that shows great promise in helping people from all cultures with a debilitating disease at a low cost, high effectiveness, and very few, if any, side effects. One wonders what a great blessing to humankind it would be if only the theories and principles of this ancient practise were applied more broadly in the world.
* * *
You are welcome to print and circulate all articles published on Clearharmony and their content, but please quote the source.